-
1
-
-
0021242388
-
Tumor heterogeneity
-
Heppner GH. Tumor heterogeneity. Cancer Res 1984; 44: 2259-2265. (Pubitemid 14110633)
-
(1984)
Cancer Research
, vol.44
, Issue.6
, pp. 2259-2265
-
-
Heppner, G.H.1
-
2
-
-
0034614637
-
The hallmarks of cancer
-
Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70. (Pubitemid 30046295)
-
(2000)
Cell
, vol.100
, Issue.1
, pp. 57-70
-
-
Hanahan, D.1
Weinberg, R.A.2
-
3
-
-
36248962105
-
The genomic landscapes of human breast and colorectal cancers
-
DOI 10.1126/science.1145720
-
Wood LD, Parsons DW, Jones S. The genomic landscapes of human breast and colorectal cancers. Science 2007; 318: 1108-1113. (Pubitemid 350134889)
-
(2007)
Science
, vol.318
, Issue.5853
, pp. 1108-1113
-
-
Wood, L.D.1
Parsons, D.W.2
Jones, S.3
Lin, J.4
Sjoblom, T.5
Leary, R.J.6
Shen, D.7
Boca, S.M.8
Barber, T.9
Ptak, J.10
Silliman, N.11
Szabo, S.12
Dezso, Z.13
Ustyanksky, V.14
Nikolskaya, T.15
Nikolsky, Y.16
Karchin, R.17
Wilson, P.A.18
Kaminker, J.S.19
Zhang, Z.20
Croshaw, R.21
Willis, J.22
Dawson, D.23
Shipitsin, M.24
Willson, J.K.V.25
Sukumar, S.26
Polyak, K.27
Ben, H.P.28
Pethiyagoda, C.L.29
Pant, P.V.K.30
Ballinger, D.G.31
Sparks, A.B.32
Hartigan, J.33
Smith, D.R.34
Suh, E.35
Papadopoulos, N.36
Buckhaults, P.37
Markowitz, S.D.38
Parmigiani, G.39
Kinzler, K.W.40
Velculescu, V.E.41
Vogelstein, B.42
more..
-
4
-
-
52149123619
-
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses
-
Jones S, Zhang X, Parsons DW. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008; 321: 1801-1806.
-
(2008)
Science
, vol.321
, pp. 1801-1806
-
-
Jones, S.1
Zhang, X.2
Parsons, D.W.3
-
6
-
-
76249121728
-
Review. Time for the epigenome
-
Review. Time for the epigenome. Nature 2010; 463: 587.
-
(2010)
Nature
, vol.463
, pp. 587
-
-
-
7
-
-
70249147655
-
Sensitive digital quantification of DNA methylation in clinical samples
-
Li M, Chen WD, Papadopoulos N, Goodman SN, Bjerregaard NC, Laurberg S et al. Sensitive digital quantification of DNA methylation in clinical samples. Nat Biotechnol 2009; 27: 858-863.
-
(2009)
Nat Biotechnol
, vol.27
, pp. 858-863
-
-
Li, M.1
Chen, W.D.2
Papadopoulos, N.3
Goodman, S.N.4
Bjerregaard, N.C.5
Laurberg, S.6
-
8
-
-
70149093912
-
Recurring mutations found by sequencing an acute myeloid leukemia genome
-
Mardis ER, Ding L, Dooling DJ, Larson DE, McLellan MD, Chen K et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009; 361: 1058-1066.
-
(2009)
N Engl J Med
, vol.361
, pp. 1058-1066
-
-
Mardis, E.R.1
Ding, L.2
Dooling, D.J.3
Larson, D.E.4
McLellan, M.D.5
Chen, K.6
-
9
-
-
55549101623
-
DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome
-
Ley TJ, Mardis ER, Ding L, Fulton B, McLellan MD, Chen K et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 2008; 456: 66-72.
-
(2008)
Nature
, vol.456
, pp. 66-72
-
-
Ley, T.J.1
Mardis, E.R.2
Ding, L.3
Fulton, B.4
McLellan, M.D.5
Chen, K.6
-
10
-
-
74449085934
-
A small-cell lung cancer genome with complex signatures of tobacco exposure
-
Pleasance ED, Stephens PJ, O'Meara S, McBride DJ, Meynert A, Jones D et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 2009; 463: 184-190.
-
(2009)
Nature
, vol.463
, pp. 184-190
-
-
Pleasance, E.D.1
Stephens, P.J.2
O'Meara, S.3
McBride, D.J.4
Meynert, A.5
Jones, D.6
-
11
-
-
74449093973
-
A comprehensive catalogue of somatic mutations from a human cancer genome
-
Pleasance ED, Cheetham RK, Stephens PJ, McBride DJ, Humphray SJ, Greenman CD et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010; 463: 191-196.
-
(2010)
Nature
, vol.463
, pp. 191-196
-
-
Pleasance, E.D.1
Cheetham, R.K.2
Stephens, P.J.3
McBride, D.J.4
Humphray, S.J.5
Greenman, C.D.6
-
12
-
-
77951139631
-
Genome remodelling in a basal-like breast cancer metastasis and xenograft
-
Ding L, Ellis MJ, Li S, Larson DE, Chen K, Wallis JW et al. Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature 2010; 464: 999-1005.
-
(2010)
Nature
, vol.464
, pp. 999-1005
-
-
Ding, L.1
Ellis, M.J.2
Li, S.3
Larson, D.E.4
Chen, K.5
Wallis, J.W.6
-
13
-
-
72949119310
-
Complex landscapes of somatic rearrangement in human breast cancer genomes
-
Stephens PJ, McBride DJ, Lin ML, Varela I, Pleasance ED, Simpson JT et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 2009; 462: 1005-1010.
-
(2009)
Nature
, vol.462
, pp. 1005-1010
-
-
Stephens, P.J.1
McBride, D.J.2
Lin, M.L.3
Varela, I.4
Pleasance, E.D.5
Simpson, J.T.6
-
14
-
-
0036561908
-
Modelling the molecular circuitry of cancer
-
Hahn WC, Weinberg RA. Modelling the molecular circuitry of cancer. Nat Rev Cancer 2002; 2: 331-341. (Pubitemid 37328946)
-
(2002)
Nature Reviews Cancer
, vol.2
, Issue.5
, pp. 331-341
-
-
Hahn, W.C.1
Weinberg, R.A.2
-
15
-
-
63049104211
-
Microenvironmental regulation of metastasis
-
Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat Rev Cancer 2009; 9: 239-252.
-
(2009)
Nat Rev Cancer
, vol.9
, pp. 239-252
-
-
Joyce, J.A.1
Pollard, J.W.2
-
16
-
-
77949613884
-
Systems medicine: A real approach for future personalized oncology?
-
Roukos DH. Systems medicine: a real approach for future personalized oncology? Pharmacogenomics 2010; 11: 283-287.
-
(2010)
Pharmacogenomics
, vol.11
, pp. 283-287
-
-
Roukos, D.H.1
-
17
-
-
70249134919
-
Molecular networks as sensors and drivers of common human diseases
-
Schadt EE. Molecular networks as sensors and drivers of common human diseases. Nature 2009; 461: 218-223.
-
(2009)
Nature
, vol.461
, pp. 218-223
-
-
Schadt, E.E.1
-
18
-
-
74749106342
-
Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care
-
Roukos DH. Novel clinico-genome network modeling for revolutionizing genotype-phenotype-based personalized cancer care. Expert Rev Mol Diagn 2010; 10: 33-48.
-
(2010)
Expert Rev Mol Diagn
, vol.10
, pp. 33-48
-
-
Roukos, D.H.1
-
19
-
-
57649124192
-
Reverse engineering the genotype-phenotype map with natural genetic variation
-
Rockman MV. Reverse engineering the genotype-phenotype map with natural genetic variation. Nature 2008; 456: 738-744.
-
(2008)
Nature
, vol.456
, pp. 738-744
-
-
Rockman, M.V.1
-
20
-
-
33646568784
-
Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world
-
DOI 10.1200/JCO.2005.05.2308
-
Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-2150. (Pubitemid 46655601)
-
(2006)
Journal of Clinical Oncology
, vol.24
, Issue.14
, pp. 2137-2150
-
-
Kamangar, F.1
Dores, G.M.2
Anderson, W.F.3
-
21
-
-
67650874081
-
Cancer statistics 2009
-
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ et al. Cancer statistics 2009. CA Cancer J Clin 2009; 59: 225-249.
-
(2009)
CA Cancer J Clin
, vol.59
, pp. 225-249
-
-
Jemal, A.1
Siegel, R.2
Ward, E.3
Hao, Y.4
Xu, J.5
Thun, M.J.6
-
22
-
-
11144242211
-
Timeline: Chemotherapy and the war on cancer
-
Chabner BA, Roberts Jr TG. Timeline: chemotherapy and the war on cancer. Nat Rev Cancer 2005; 5: 65-72.
-
(2005)
Nat Rev Cancer
, vol.5
, pp. 65-72
-
-
Chabner, B.A.1
Roberts Jr., T.G.2
-
23
-
-
19344364880
-
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomized trials
-
Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
-
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005; 365: 1687-1717.
-
(2005)
Lancet
, vol.365
, pp. 1687-1717
-
-
-
24
-
-
77952304670
-
Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch DLD2 trial
-
Songun I, Putter H, Kranenbarg EM, Sasako M, van de Velde CJ. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch DLD2 trial. Lancet Oncol 2010; 11: 439-449.
-
(2010)
Lancet Oncol
, vol.11
, pp. 439-449
-
-
Songun, I.1
Putter, H.2
Kranenbarg, E.M.3
Sasako, M.4
Van De Velde, C.J.5
-
25
-
-
33745726677
-
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer
-
Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
-
(2006)
N Engl J Med
, vol.355
, pp. 11-20
-
-
Cunningham, D.1
Allum, W.H.2
Stenning, S.P.3
Thompson, J.N.4
Van De Velde, C.J.5
Nicolson, M.6
-
26
-
-
0035818048
-
Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastro-esophageal junction
-
Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastro-esophageal junction. N Engl J Med 2001; 345: 725-730.
-
(2001)
N Engl J Med
, vol.345
, pp. 725-730
-
-
MacDonald, J.S.1
Smalley, S.R.2
Benedetti, J.3
Hundahl, S.A.4
Estes, N.C.5
Stemmermann, G.N.6
-
27
-
-
35748946650
-
Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine
-
DOI 10.1056/NEJMoa072252
-
Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357: 1810-1820. (Pubitemid 350044801)
-
(2007)
New England Journal of Medicine
, vol.357
, Issue.18
, pp. 1810-1820
-
-
Sakuramoto, S.1
Sasako, M.2
Yamaguchi, T.3
Kinoshita, T.4
Fujii, M.5
Nashimoto, A.6
Furukawa, H.7
Nakajima, T.8
Ohashi, Y.9
Imamura, H.10
Higashino, M.11
Yamamura, Y.12
Kurita, A.13
Arai, K.14
-
28
-
-
62149146888
-
Genome-wide association studies and aggressive surgery toward individualized prevention, and improved local control and overall survival for gastric cancer
-
Roukos DH. Genome-wide association studies and aggressive surgery toward individualized prevention, and improved local control and overall survival for gastric cancer. Ann Surg Oncol 2009; 16: 795-798.
-
(2009)
Ann Surg Oncol
, vol.16
, pp. 795-798
-
-
Roukos, D.H.1
-
29
-
-
0028113345
-
A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1
-
Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66-71. (Pubitemid 24345325)
-
(1994)
Science
, vol.266
, Issue.5182
, pp. 66-71
-
-
Miki, Y.1
Swensen, J.2
Shattuck-Eidens, D.3
Futreal, P.A.4
Harshman, K.5
Tavtigian, S.6
Liu, Q.7
Cochran, C.8
Bennett, L.M.9
Ding, W.10
Bell, R.11
Rosenthal, J.12
Hussey, C.13
Tran, T.14
McClure, M.15
Frye, C.16
Hattier, T.17
Phelps, R.18
Haugen-Strano, A.19
Katcher, H.20
Yakumo, K.21
Gholami, Z.22
Shaffer, D.23
Stone, S.24
Bayer, S.25
Wray, C.26
Bogden, R.27
Dayananth, P.28
Ward, J.29
Tonin, P.30
Narod, S.31
Bristow, P.K.32
Norris, F.H.33
Helvering, L.34
Morrison, P.35
Rosteck, P.36
Lai, M.37
Barrett, J.C.38
Lewis, C.39
Neuhausen, S.40
Cannon-Albright, L.41
Goldgar, D.42
Wiseman, R.43
Kamb, A.44
Skolnick, M.H.45
more..
-
30
-
-
0006713602
-
Identification of the breast cancer susceptibility gene BRCA2
-
DOI 10.1038/378789a0
-
Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 789-792. (Pubitemid 26004412)
-
(1995)
Nature
, vol.378
, Issue.6559
, pp. 789-792
-
-
Wooster, R.1
Bignell, G.2
Lancaster, J.3
Swift, S.4
Seal, S.5
Mangion, J.6
Collins, N.7
Gregory, S.8
Gumbs, C.9
Micklem, G.10
Barfoot, R.11
Hamoudl, R.12
Patel, S.13
Rice, C.14
Biggs, P.15
Hashim, Y.16
Smith, A.17
Connor, F.18
Arason, A.19
Gudmundsson, J.20
Ficenec, D.21
Kelsell, D.22
Ford, D.23
Tonin, P.24
Bishop, D.T.25
Spurr, N.K.26
Ponder, B.A.J.27
Eeles, R.28
Peto, J.29
Devilee, P.30
Cornelisse, C.31
Lynch, H.32
Narod, S.33
Lenoir, G.34
Egilsson, V.35
Barkadottir, R.B.36
Easton, D.F.37
Bentley, D.R.38
Futreal, P.A.39
Ashworth, A.40
Stratton, M.R.41
more..
-
31
-
-
0032568370
-
E-cadherin germline mutations in familial gastric cancer
-
DOI 10.1038/32918
-
Guilford P, Hopkins J, Harraway J, McLeod M, McLeod N, Harawira P et al. E-cadherin germline mutations in familial gastric cancer. Nature 1998; 392: 402-405. (Pubitemid 28168738)
-
(1998)
Nature
, vol.392
, Issue.6674
, pp. 402-405
-
-
Guilford, P.1
Hopkins, J.2
Harraway, J.3
McLeod, M.4
McLeod, N.5
Harawira, P.6
Taite, H.7
Scoular, R.8
Miller, A.9
Reeve, A.E.10
-
32
-
-
4544374528
-
BRCA1 and BRCA2: 1994 and beyond
-
DOI 10.1038/nrc1431
-
Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 2004; 4: 665-676. (Pubitemid 39215065)
-
(2004)
Nature Reviews Cancer
, vol.4
, Issue.9
, pp. 665-676
-
-
Narod, S.A.1
Foulkes, W.D.2
-
33
-
-
73349135021
-
CDH1 testing: Can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer?
-
Ziogas D, Roukos DH. CDH1 testing: can it predict the prophylactic or therapeutic nature of total gastrectomy in hereditary diffuse gastric cancer? Ann Surg Oncol 2009; 16: 2678-2681.
-
(2009)
Ann Surg Oncol
, vol.16
, pp. 2678-2681
-
-
Ziogas, D.1
Roukos, D.H.2
-
34
-
-
85047686032
-
Genome-wide association studies: How predictable is a person's cancer risk?
-
Roukos DH. Genome-wide association studies: how predictable is a person's cancer risk? Expert Rev Anticancer Ther 2009; 9: 389-392.
-
(2009)
Expert Rev Anticancer Ther
, vol.9
, pp. 389-392
-
-
Roukos, D.H.1
-
35
-
-
2342591455
-
The discovery of receptor tyrosine kinases: Targets for cancer therapy
-
Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004; 4: 361-370. (Pubitemid 38579482)
-
(2004)
Nature Reviews Cancer
, vol.4
, Issue.5
, pp. 361-370
-
-
Gschwind, A.1
Fischer, O.M.2
Ullrich, A.3
-
36
-
-
67649472398
-
Novel anticancer targets: Revisiting ERBB2 and discovering ERBB3
-
Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009; 9: 463-475.
-
(2009)
Nat Rev Cancer
, vol.9
, pp. 463-475
-
-
Baselga, J.1
Swain, S.M.2
-
37
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2
-
DOI 10.1056/NEJM200103153441101
-
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792. (Pubitemid 32222155)
-
(2001)
New England Journal of Medicine
, vol.344
, Issue.11
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
Fuchs, H.4
Paton, V.5
Bajamonde, A.6
Fleming, T.7
Eiermann, W.8
Wolter, J.9
Pegram, M.10
Baselga, J.11
Norton, L.12
-
38
-
-
70350204423
-
Efficacy results from the ToGA trial: A phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC)
-
(abstr LBA4509)
-
Van Cutsem E, Kang Y, Chung H, Shen A, Sawaki F, Lordick J et al. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). J Clin Oncol 2009; 27(Suppl): 18s (abstr LBA4509).
-
(2009)
J Clin Oncol
, vol.27
, Issue.SUPPL.
-
-
Van Cutsem, E.1
Kang, Y.2
Chung, H.3
Shen, A.4
Sawaki, F.5
Lordick, J.6
-
39
-
-
74649083025
-
Targeting gastric cancer with trastuzumab: New clinical practice and innovative developments to overcome resistance
-
Roukos DH. Targeting gastric cancer with trastuzumab: new clinical practice and innovative developments to overcome resistance. Ann Surg Oncol 2010; 17: 14-17.
-
(2010)
Ann Surg Oncol
, vol.17
, pp. 14-17
-
-
Roukos, D.H.1
-
40
-
-
73349121354
-
Clinical cancer advances 2009: Major research advances in cancer treatment, prevention, and screening-a report from the American society of clinical oncology
-
Petrelli NJ, Winer EP, Brahmer J, Dubey S, Smith S, Thomas C et al. Clinical cancer advances 2009: major research advances in cancer treatment, prevention, and screening-a report from the American society of clinical oncology. J Clin Oncol 2009; 27: 6052-6069.
-
(2009)
J Clin Oncol
, vol.27
, pp. 6052-6069
-
-
Petrelli, N.J.1
Winer, E.P.2
Brahmer, J.3
Dubey, S.4
Smith, S.5
Thomas, C.6
-
41
-
-
26844457534
-
The distinctive nature of HER2-positive breast cancers
-
DOI 10.1056/NEJMp058197
-
Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med 2005; 353: 1652-1654. (Pubitemid 41464703)
-
(2005)
New England Journal of Medicine
, vol.353
, Issue.16
, pp. 1652-1654
-
-
Burstein, H.J.1
-
42
-
-
26844559765
-
Trastuzumab in the treatment of breast cancer
-
DOI 10.1056/NEJMe058196
-
Hortobagyi GN. Trastuzumab in the treatment of breast cancer. N Engl J Med 2005; 353: 1734-1736. (Pubitemid 41464714)
-
(2005)
New England Journal of Medicine
, vol.353
, Issue.16
, pp. 1734-1736
-
-
Hortobagyi, G.N.1
-
43
-
-
33845914783
-
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial
-
DOI 10.1016/S0140-6736(07)60028-2, PII S0140673607600282
-
Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369: 29-36. (Pubitemid 46039831)
-
(2007)
Lancet
, vol.369
, Issue.9555
, pp. 29-36
-
-
Smith, I.1
Procter, M.2
Gelber, R.D.3
Guillaume, S.4
Feyereislova, A.5
Dowsett, M.6
Goldhirsch, A.7
Untch, M.8
Mariani, G.9
Baselga, J.10
Kaufmann, M.11
Cameron, D.12
Bell, R.13
Bergh, J.14
Coleman, R.15
Wardley, A.16
Harbeck, N.17
Lopez, R.I.18
Mallmann, P.19
Gelmon, K.20
Wilcken, N.21
Wist, E.22
Sanchez Rovira, P.23
Piccart-Gebhart, M.J.24
more..
-
44
-
-
36148961294
-
Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer
-
Perez EA, Romond EH, Suman VJ, Jeong NE, Davidson CE, Geyer S et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. J Clin Oncol 2007; 25: 512.
-
(2007)
J Clin Oncol
, vol.25
, pp. 512
-
-
Perez, E.A.1
Romond, E.H.2
Suman, V.J.3
Jeong, N.E.4
Davidson, C.E.5
Geyer, S.6
-
45
-
-
26844536978
-
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
-
DOI 10.1056/NEJMoa052122
-
Romond EH, Perez EA, Bryant J, Suman VJ, Geyer Jr CE, Davidson NE et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1684. (Pubitemid 41464706)
-
(2005)
New England Journal of Medicine
, vol.353
, Issue.16
, pp. 1673-1684
-
-
Romond, E.H.1
Perez, E.A.2
Bryant, J.3
Suman, V.J.4
Geyer Jr., C.E.5
Davidson, N.E.6
Tan-Chiu, E.7
Martino, S.8
Paik, S.9
Kaufman, P.A.10
Swain, S.M.11
Pisansky, T.M.12
Fehrenbacher, L.13
Kutteh, L.A.14
Vogel, V.G.15
Visscher, D.W.16
Yothers, G.17
Jenkins, R.B.18
Brown, A.M.19
Dakhil, S.R.20
Mamounas, E.P.21
Lingle, W.L.22
Klein, P.M.23
Ingle, J.N.24
Wolmark, N.25
more..
-
46
-
-
26844503270
-
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
-
DOI 10.1056/NEJMoa052306
-
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-1672. (Pubitemid 41464705)
-
(2005)
New England Journal of Medicine
, vol.353
, Issue.16
, pp. 1659-1672
-
-
Piccart-Gebhart, M.J.1
Procter, M.2
Leyland-Jones, B.3
Goldhirsch, A.4
Untch, M.5
Smith, I.6
Gianni, L.7
Baselga, J.8
Bell, R.9
Jackisch, C.10
Cameron, D.11
Dowsett, M.12
Barrios, C.H.13
Steger, G.14
Huang, C.-S.15
Andersson, M.16
Inbar, M.17
Lichinitser, M.18
Lang, I.19
Nitz, U.20
Iwata, H.21
Thomssen, C.22
Lohrisch, C.23
Suter, T.M.24
Ruschoff, J.25
Suto, T.26
Greatorex, V.27
Ward, C.28
Straehle, C.29
McFadden, E.30
Dolci, M.S.31
Gelber, R.D.32
more..
-
47
-
-
33947317453
-
BCIRG 006: II interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxo-rubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel carboplatin and trastuzumab in Her2neu positive early breast cancer patients
-
December 14-17 San Antonio, Texas
-
Slamon D, Eiermann W, Robert NJ, Pienkowski T, Martin M, Pawlicki M et al. BCIRG 006: II interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxo-rubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in Her2neu positive early breast cancer patients. The 2006 San Antonio Breast Cancer Symposium; December 14-17, 2006; San Antonio, Texas.
-
(2006)
The 2006 San Antonio Breast Cancer Symposium
-
-
Slamon, D.1
Eiermann, W.2
Robert, N.J.3
Pienkowski, T.4
Martin, M.5
Pawlicki, M.6
-
48
-
-
33645720799
-
Phase III randomized trial comparing doxorubicin and cyclo-phosphamide followed by docetaxel with doxorubicin and cyclo-phosphamide followed by docetaxel and trastuzumab with docetaxel carboplatin and trastuzumab in HER2 positive early breast cancer patients: BCIRG 006 study
-
December 8-11 San Antonio, Texas
-
Slamon D, Eiermann W, Robert NJ, Pienkowski T, Martin M, Pawlicki M et al. Phase III randomized trial comparing doxorubicin and cyclo-phosphamide followed by docetaxel with doxorubicin and cyclo-phosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER2 positive early breast cancer patients: BCIRG 006 study. The 2005 San Antonio Breast Cancer Symposium; December 8-11, 2005; San Antonio, Texas.
-
(2005)
The 2005 San Antonio Breast Cancer Symposium
-
-
Slamon, D.1
Eiermann, W.2
Robert, N.J.3
Pienkowski, T.4
Martin, M.5
Pawlicki, M.6
-
49
-
-
33344478381
-
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer
-
DOI 10.1056/NEJMoa053028
-
Joensuu H, Kellokumpu-Lehtinen PL, Bono P, Alanko T, Kataja V, Asola R et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354: 809-820. (Pubitemid 43290919)
-
(2006)
New England Journal of Medicine
, vol.354
, Issue.8
, pp. 809-820
-
-
Joensuu, H.1
Kellokumpu-Lehtinen, P.-L.2
Bono, P.3
Alanko, T.4
Kataja, V.5
Asola, R.6
Utriainen, T.7
Kokko, R.8
Hemminki, A.9
Tarkkanen, M.10
Turpeenniemi-Hujanen, T.11
Jyrkkio, S.12
Flander, M.13
Helle, L.14
Ingalsuo, S.15
Johansson, K.16
Jaaskelainen, A.-S.17
Pajunen, M.18
Rauhala, M.19
Kaleva-Kerola, J.20
Salminen, T.21
Leinonen, M.22
Elomaa, I.23
Isola, J.24
more..
-
50
-
-
46149111250
-
Trastuzumab in the adjuvant treatment of early-stage breast cancer: A systematic review and meta-analysis of randomized controlled trials
-
DOI 10.1634/theoncologist.2008-0001
-
Dahabreh IJ, Linardou H, Siannis F, Fountzilas G, Murray S. Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist 2008; 13: 620-630. (Pubitemid 351904907)
-
(2008)
Oncologist
, vol.13
, Issue.6
, pp. 620-630
-
-
Dahabreh, I.J.1
Linardou, H.2
Siannis, F.3
Fountzilas, G.4
Murray, S.5
-
51
-
-
58149354867
-
Quo vadis with targeted drugs in the 21st century?
-
Bergh J. Quo vadis with targeted drugs in the 21st century? J Clin Oncol 2009; 27: 2-5.
-
(2009)
J Clin Oncol
, vol.27
, pp. 2-5
-
-
Bergh, J.1
-
52
-
-
66749140976
-
Mea culpa with cancer-targeted therapy: New thinking and new agents design for novel, causal networks-based, personalized biomedicine
-
Roukos DH. Mea culpa with cancer-targeted therapy: new thinking and new agents design for novel, causal networks-based, personalized biomedicine. Expert Rev Mol Diagn 2009; 9: 217-221.
-
(2009)
Expert Rev Mol Diagn
, vol.9
, pp. 217-221
-
-
Roukos, D.H.1
-
53
-
-
24944578615
-
Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: Case closed or is the jury still out?
-
Gandara DR, Gumerlock PH. Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: case closed or is the jury still out? J Clin Oncol 2005; 23: 5856-5858.
-
(2005)
J Clin Oncol
, vol.23
, pp. 5856-5858
-
-
Gandara, D.R.1
Gumerlock, P.H.2
-
54
-
-
70349472886
-
New, but not improved? Incorporating comparative-effectiveness information into FDA labeling
-
Stafford RS, Wagner TH, Lavori PW. New, but not improved? Incorporating comparative-effectiveness information into FDA labeling. N Engl J Med 2009; 361: 1230-1233.
-
(2009)
N Engl J Med
, vol.361
, pp. 1230-1233
-
-
Stafford, R.S.1
Wagner, T.H.2
Lavori, P.W.3
-
55
-
-
63849088630
-
Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer
-
Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417.
-
(2009)
N Engl J Med
, vol.360
, pp. 1408-1417
-
-
Van Cutsem, E.1
Köhne, C.H.2
Hitre, E.3
Zaluski, J.4
Chang Chien, C.R.5
Makhson, A.6
-
56
-
-
75249087060
-
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): An open label, randomised phase 3 trial
-
Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11: 121.
-
(2010)
Lancet Oncol
, vol.11
, pp. 121
-
-
Mitsudomi, T.1
Morita, S.2
Yatabe, Y.3
Negoro, S.4
Okamoto, I.5
Tsurutani, J.6
-
57
-
-
66249090533
-
Systems biology: When it is time to die
-
Bastiaens P. Systems biology: when it is time to die. Nature 2009; 459: 334-335.
-
(2009)
Nature
, vol.459
, pp. 334-335
-
-
Bastiaens, P.1
-
58
-
-
70350593945
-
Current concerns and challenges towards tailored anti-angiogenic therapy in cancer
-
Roukos DH, Tzakos A, Zografos G. Current concerns and challenges towards tailored anti-angiogenic therapy in cancer. Expert Rev Anticancer Ther 2009; 9: 1413-1416.
-
(2009)
Expert Rev Anticancer Ther
, vol.9
, pp. 1413-1416
-
-
Roukos, D.H.1
Tzakos, A.2
Zografos, G.3
-
59
-
-
62649101158
-
Cancer: The nuances of therapy
-
Ellis LM, Reardon DA. Cancer: the nuances of therapy. Nature 2009; 458: 290-292.
-
(2009)
Nature
, vol.458
, pp. 290-292
-
-
Ellis, L.M.1
Reardon, D.A.2
-
60
-
-
68849115626
-
Micrometastases or isolated tumor cells and the outcome of breast cancer
-
De Boer M, van Deurzen CH, van Dijck JA, Borm GF, van Diest PJ, Adang EM et al. Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med 2009; 361: 653-663.
-
(2009)
N Engl J Med
, vol.361
, pp. 653-663
-
-
De Boer, M.1
Van Deurzen, C.H.2
Van Dijck, J.A.3
Borm, G.F.4
Van Diest, P.J.5
Adang, E.M.6
-
61
-
-
70449641339
-
Isolated tumor cells in breast cancer
-
Roukos DH. Isolated tumor cells in breast cancer. N Engl J Med 2009; 361: 1994-1995.
-
(2009)
N Engl J Med
, vol.361
, pp. 1994-1995
-
-
Roukos, D.H.1
-
62
-
-
60849097255
-
Gene-expression signatures in breast cancer
-
Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009; 360: 790-800.
-
(2009)
N Engl J Med
, vol.360
, pp. 790-800
-
-
Sotiriou, C.1
Pusztai, L.2
-
63
-
-
19944422061
-
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
-
DOI 10.1056/NEJMoa041588
-
Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351: 2817-2826. (Pubitemid 40051905)
-
(2004)
New England Journal of Medicine
, vol.351
, Issue.27
, pp. 2817-2826
-
-
Paik, S.1
Shak, S.2
Tang, G.3
Kim, C.4
Baker, J.5
Cronin, M.6
Baehner, F.L.7
Walker, M.G.8
Watson, D.9
Park, T.10
Hiller, W.11
Fisher, E.R.12
Wickerham, D.L.13
Bryant, J.14
Wolmark, N.15
-
64
-
-
0037137519
-
A gene-expression signature as a predictor of survival in breast cancer
-
DOI 10.1056/NEJMoa021967
-
Van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347: 1999-2009. (Pubitemid 35461656)
-
(2002)
New England Journal of Medicine
, vol.347
, Issue.25
, pp. 1999-2009
-
-
Van De Vijver, M.J.1
He, Y.D.2
Van 'T Veer, L.J.3
Dai, H.4
Hart, A.A.M.5
Voskuil, D.W.6
Schreiber, G.J.7
Peterse, J.L.8
Roberts, C.9
Marton, M.J.10
Parrish, M.11
Atsma, D.12
Witteveen, A.13
Glas, A.14
Delahaye, L.15
Van Der Velde, T.16
Bartelink, H.17
Rodenhuis, S.18
Rutgers, E.T.19
Friend, S.H.20
Bernards, R.21
more..
-
65
-
-
62449163752
-
Twenty-one-gene assay: Challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer
-
Roukos DH. Twenty-one-gene assay: challenges and promises in translating personal genomics and whole-genome scans into personalized treatment of breast cancer. J Clin Oncol 2009; 27: 1337-1338.
-
(2009)
J Clin Oncol
, vol.27
, pp. 1337-1338
-
-
Roukos, D.H.1
-
66
-
-
33746887084
-
Molecular signatures predict outcomes of breast cancer
-
DOI 10.1056/NEJMe068145
-
O'Shaughnessy JA. Molecular signatures predict outcomes of breast cancer. N Engl J Med 2006; 355: 615-617. (Pubitemid 44200656)
-
(2006)
New England Journal of Medicine
, vol.355
, Issue.6
, pp. 615-617
-
-
O'Shaughnessy, J.A.1
-
68
-
-
77951650701
-
HER2 signatures in breast cancer: Ready to go to print?
-
Eichhorn PJ, Baselga J. HER2 signatures in breast cancer: ready to go to print? J Clin Oncol 2010; 28: 1809-1810.
-
(2010)
J Clin Oncol
, vol.28
, pp. 1809-1810
-
-
Eichhorn, P.J.1
Baselga, J.2
-
69
-
-
79953058756
-
-
Individualized Patients Personalized Care PIPC: Washington, DC (Accessed April 17, 2009)
-
Partnership to Improve Patient Care. Individualized Patients Personalized Care 2009. PIPC: Washington, DC http://www.improvepatientcare.org/ individualized-patients-personalized-care (Accessed April 17, 2009).
-
(2009)
Partnership to Improve Patient Care
-
-
-
70
-
-
53649106195
-
Next-generation DNA sequencing
-
Shendure J, Ji H. Next-generation DNA sequencing. Nat Biotechnol 2008; 26: 1135-1145.
-
(2008)
Nat Biotechnol
, vol.26
, pp. 1135-1145
-
-
Shendure, J.1
Ji, H.2
-
71
-
-
77950607162
-
Bionetworks-based personalized medicine vs comparative-effectiveness research or harmonization of both in cancer management?
-
Roukos DH. Bionetworks-based personalized medicine vs comparative-effectiveness research or harmonization of both in cancer management? Expert Rev Mol Diagn 2010; 10: 247-250.
-
(2010)
Expert Rev Mol Diagn
, vol.10
, pp. 247-250
-
-
Roukos, D.H.1
-
72
-
-
75749155513
-
Valid concerns
-
Valid concerns. Nature 2010; 463: 401-402.
-
(2010)
Nature
, vol.463
, pp. 401-402
-
-
-
73
-
-
73849149841
-
2020 visions personalized medicine
-
Goldstein DB. 2020 visions personalized medicine. Nature 2010; 463: 27.
-
(2010)
Nature
, vol.463
, pp. 27
-
-
Goldstein, D.B.1
-
74
-
-
56449111358
-
Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235
-
Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 2008; 68: 9221-9230.
-
(2008)
Cancer Res
, vol.68
, pp. 9221-9230
-
-
Eichhorn, P.J.1
Gili, M.2
Scaltriti, M.3
Serra, V.4
Guzman, M.5
Nijkamp, W.6
-
75
-
-
77249119762
-
The landscape of somatic copy-number alteration across human cancers
-
Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J et al. The landscape of somatic copy-number alteration across human cancers. Nature 2010; 463: 899-905.
-
(2010)
Nature
, vol.463
, pp. 899-905
-
-
Beroukhim, R.1
Mermel, C.H.2
Porter, D.3
Wei, G.4
Raychaudhuri, S.5
Donovan, J.6
-
76
-
-
77950083955
-
Heteroplasmic mitochondrial DNA mutations in normal and tumour cells
-
He Y, Wu J, Dressman DC, Iacobuzio-Donahue C, Markowitz SD, Velculescu VE et al. Heteroplasmic mitochondrial DNA mutations in normal and tumour cells. Nature 2010; 464: 610-614.
-
(2010)
Nature
, vol.464
, pp. 610-614
-
-
He, Y.1
Wu, J.2
Dressman, D.C.3
Iacobuzio-Donahue, C.4
Markowitz, S.D.5
Velculescu, V.E.6
-
77
-
-
49149112491
-
Risk factors for the incidence of breast cancer: Do they affect survival from the disease?
-
Barnett GC, Shah M, Redman K, Easton DF, Ponder BA, Pharoah PD. Risk factors for the incidence of breast cancer: do they affect survival from the disease? J Clin Oncol 2008; 26: 3310-3316.
-
(2008)
J Clin Oncol
, vol.26
, pp. 3310-3316
-
-
Barnett, G.C.1
Shah, M.2
Redman, K.3
Easton, D.F.4
Ponder, B.A.5
Pharoah, P.D.6
-
78
-
-
45949085378
-
Polygenes, risk prediction, and targeted prevention of breast cancer
-
DOI 10.1056/NEJMsa0708739
-
Pharoah PD, Antoniou AC, Easton DF, Ponder BA. Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med 2008; 358: 2796-2803. (Pubitemid 351930854)
-
(2008)
New England Journal of Medicine
, vol.358
, Issue.26
, pp. 2796-2803
-
-
Pharoah, P.D.P.1
Antoniou, A.C.2
Easton, D.F.3
Ponder, B.A.J.4
-
79
-
-
77949578084
-
Performance of common genetic variants in breast-cancer risk models
-
Wacholder S, Hartge P, Prentice R, Garcia-Closas M, Feigelson HS, Diver WR et al. Performance of common genetic variants in breast-cancer risk models. N Engl J Med 2010; 362: 986-993.
-
(2010)
N Engl J Med
, vol.362
, pp. 986-993
-
-
Wacholder, S.1
Hartge, P.2
Prentice, R.3
Garcia-Closas, M.4
Feigelson, H.S.5
Diver, W.R.6
-
80
-
-
0019183253
-
On the nature of susceptibility to cancer. The presidential address
-
Miller DG. On the nature of susceptibility to cancer. The presidential address. Cancer 1980; 46: 1307-1318. (Pubitemid 11253510)
-
(1980)
Cancer
, vol.46
, Issue.6
, pp. 1307-1318
-
-
Miller, D.G.1
-
81
-
-
38449094794
-
Oncogenic transformation and experimental models of human cancer
-
DOI 10.2741/2661
-
Schinzel AC, Hahn WC. Oncogenic transformation and experimental models of human cancer. Front Biosci 2008; 13: 71-84. (Pubitemid 351594764)
-
(2008)
Frontiers in Bioscience
, vol.13
, Issue.1
, pp. 71-84
-
-
Schinzel, A.C.1
Hahn, W.C.2
-
82
-
-
36949025507
-
Genetic progression and the waiting time to cancer
-
Beerenwinkel N, Antal T, Dingli D, Traulsen A, Kinzler KW, Velculescu VE et al. Genetic progression and the waiting time to cancer. PLoS Comput Biol 2007; 3: e225.
-
(2007)
PLoS Comput Biol
, vol.3
-
-
Beerenwinkel, N.1
Antal, T.2
Dingli, D.3
Traulsen, A.4
Kinzler, K.W.5
Velculescu, V.E.6
-
83
-
-
69449090120
-
Panel members. Thresholds for therapies: Highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009
-
Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ, Panel members. Thresholds for therapies: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009; 20: 1319-1329.
-
(2009)
Ann Oncol
, vol.20
, pp. 1319-1329
-
-
Goldhirsch, A.1
Ingle, J.N.2
Gelber, R.D.3
Coates, A.S.4
Thürlimann, B.5
Senn, H.J.6
-
84
-
-
76749112093
-
From tumor size and HER2 status to systems oncology for very early breast cancer treatment
-
Roukos DH, Ziogas D. From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev Anticancer Ther 2010; 10: 123-128.
-
(2010)
Expert Rev Anticancer Ther
, vol.10
, pp. 123-128
-
-
Roukos, D.H.1
Ziogas, D.2
-
85
-
-
70349667568
-
Drug discovery: Propping up a destructive regime
-
Peterson RT. Drug discovery: propping up a destructive regime. Nature 2009; 461: 599-600.
-
(2009)
Nature
, vol.461
, pp. 599-600
-
-
Peterson, R.T.1
-
86
-
-
70449659897
-
Chemical biology: A notch above other inhibitors
-
Arora PS, Ansari AZ. Chemical biology: a notch above other inhibitors. Nature 2009; 462: 171-173.
-
(2009)
Nature
, vol.462
, pp. 171-173
-
-
Arora, P.S.1
Ansari, A.Z.2
-
87
-
-
77950412216
-
The human genome at ten
-
The human genome at ten. Nature 2010; 464: 649-650.
-
(2010)
Nature
, vol.464
, pp. 649-650
-
-
-
88
-
-
77950440741
-
Has the revolution arrived?
-
Collins F. Has the revolution arrived? Nature 2010; 464: 674-675.
-
(2010)
Nature
, vol.464
, pp. 674-675
-
-
Collins, F.1
-
89
-
-
77950456427
-
Multiple personal genomes await
-
Venter JC. Multiple personal genomes await. Nature 2010; 464: 676-677.
-
(2010)
Nature
, vol.464
, pp. 676-677
-
-
Venter, J.C.1
-
90
-
-
77950448106
-
Point: Hypotheses first
-
Weinberg R. Point: hypotheses first. Nature 2010; 464: 678.
-
(2010)
Nature
, vol.464
, pp. 678
-
-
Weinberg, R.1
-
91
-
-
77950441808
-
Counterpoint: Data first
-
Golub T. Counterpoint: data first. Nature 2010; 464: 679.
-
(2010)
Nature
, vol.464
, pp. 679
-
-
Golub, T.1
-
92
-
-
77952509768
-
Human genome at ten: The sequence explosion
-
Human genome at ten: the sequence explosion. Nature 2010; 464: 670-671.
-
(2010)
Nature
, vol.464
, pp. 670-671
-
-
-
93
-
-
77950393253
-
Human genome at ten: The human race
-
Abbott A. Human genome at ten: the human race. Nature 2010; 464: 668-669.
-
(2010)
Nature
, vol.464
, pp. 668-669
-
-
Abbott, A.1
-
94
-
-
77950398306
-
Human genome at ten: Life is complicated
-
Check Hayden E. Human genome at ten: life is complicated. Nature 2010; 464: 664-667.
-
(2010)
Nature
, vol.464
, pp. 664-667
-
-
Check Hayden, E.1
|